menu
    • menu
    [{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Fulvestrant","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Nextech","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Nextech"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"RLY-2608","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Relay Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RLY-2608","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Relay Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for RLY-2608

    Menu

    RLY-2608

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Relay Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLY-2608,Palbociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Relay Therapeutics Announces Positive Interim Data for RLY-2608 in Cancer Treatment

                            Details : RLY-2608 is a PI3K alpha inhibitor, small molecule, which is being evaluated for the treatment of patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer.

                            Brand Name : RLY-2608

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 09, 2024

                            Lead Product(s) : RLY-2608,Palbociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Relay Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLY-2608,Atirmociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Relay Therapeutics, Pfizer to Collaborate on Atirmociclib and RLY-2608 Clinical Trial

                            Details : The collaboration with Pfizer to evaluate atirmociclib, selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer.

                            Brand Name : RLY-2608

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 05, 2024

                            Lead Product(s) : RLY-2608,Atirmociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Relay Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLY-2608,Fulvestrant,Palbociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Nextech

                            Deal Size : $30.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Relay Therapeutics Announces $30 Million Private Placement Financing

                            Details : Relay Therapeutics expects to use net proceeds to advance RLY-2608, , a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia.

                            Brand Name : RLY-2608

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 08, 2024

                            Lead Product(s) : RLY-2608,Fulvestrant,Palbociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Nextech

                            Deal Size : $30.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Relay Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLY-2608,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI...

                            Details : RLY-2608 is a selective inhibitors of PI3K alpha. PI3K alpha is the most frequently mutated in all cancers, with oncogenic mutations detected in about 13% of patients with solid tumors. RLY-2608 is currently being evaluated for advanced solid tumors with...

                            Brand Name : RLY-2608

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 18, 2023

                            Lead Product(s) : RLY-2608,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Relay Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Relay Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RLY-2608,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR

                            Details : RLY-2608 is a selective inhibitors of PI3K alpha. PI3K alpha is the most frequently mutated in all cancers, with oncogenic mutations detected in about 13% of patients with solid tumors. RLY-2608 is currently being evaluated for advanced solid tumors with...

                            Brand Name : RLY-2608

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 06, 2023

                            Lead Product(s) : RLY-2608,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth